Regeneron Pharmaceuticals, IncNasdaq: REGN
Health Care · Biotechnology
$702.19
-0.69%
Vol: 536K
Research Digest
Friday, May 1, 2026
Regeneron shares fell 7.1% despite strong Q1 beat due to FDA approval delays and profitability concerns.
Regeneron Q1 2026 strong results with 19% revenue growth to $3.6B and adjusted EPS $9.47, exceeding analyst expectations by $0.37. Shares declined 7.1% after market close due to profitability concerns and FDA inaction on Eylea HD prefilled syringe approval. Key achievements: FDA approval of Otarmeni, first gene therapy for genetic hearing loss, and collaboration with Telix Pharmaceuticals on radiopharmaceuticals. Dupixent sales surged 33% to $4.9B, Eylea HD surged 52% to $468.4M. Authorized $3B share repurchases.
Previous Market Intelligence
13 daysApr 30Regeneron reports Q1 2026 earnings beat but stock drops 8.07% due to declining GAAP earnings and FDA approval delays.Negative▶
Regeneron reported Q1 2026 revenues increased 19% to $3.6 billion with strong product performance from Dupixent (33% growth) and EYLEA HD (52% growth). Despite non-GAAP net income rising 12% to $1.04 billion, GAAP earnings fell 10% to $727 million, disappointing investors. Truist Securities lowered its price target to $769 from $801 citing FDA inaction on Eylea HD prefilled syringe approval. The company also announced favorable Medicaid pricing agreements with the U.S. government.
Apr 16Regeneron partners with Telix for radiopharma collaboration; $40M upfront + $2.1B milestonesPositive▶
Regeneron and Telix Pharmaceuticals announced 50/50 cost and profit-sharing radiopharma partnership with $40M upfront and up to $2.1B in milestone payments. Q4 2025 earnings beat with 3% revenue growth and $11.44 adjusted EPS. Dupixent approved in EU for children with chronic spontaneous urticaria. Analyst consensus Buy with $821–828 price target, 7.8–10.6% upside.
Apr 15Regeneron FDA approves EYLEA HD extended dosing up to 20 weeks; Telix collaboration announced; Q1 earnings due April 29.Positive▶
Regeneron received FDA approval to extend EYLEA HD dosing intervals up to every 20 weeks for wet AMD and DME. Company announced 50/50 strategic collaboration with Telix Pharmaceuticals for next-gen radiopharmaceutical development. Dupixent approved in EU for pediatric chronic spontaneous urticaria. Q1 2026 earnings and conference call scheduled for April 29.
Apr 14Regeneron announces $4.3B radiopharma collaboration with Telix and EU approval for Dupixent in young children.Positive▶
Regeneron announced strategic radiopharma collaboration with Telix Pharmaceuticals worth up to $4.3B, with $40M upfront. EU approved Dupixent for moderate-to-severe chronic spontaneous urticaria in children aged 2-11. Q1 2026 earnings due April 29. Stock at $748.87 with 37% 1-year performance driven by Eylea HD and Dupixent COPD expansion.
Apr 13Regeneron secures CHMP opinion for Dupixent CSU pediatric approval; Q1 earnings set for April 29.Positive▶
Regeneron and Sanofi received positive CHMP opinion recommending EU approval of Dupixent for chronic spontaneous urticaria in children aged 2-11. Company reported positive Phase 3 results for obesity treatment via partnership with Hansoh. Q1 2026 earnings scheduled for April 29. Morgan Stanley raised price target to $796 from $769. Buy consensus from 21 analysts with target of $825.24.
Apr 10Regeneron targets Japan approval for Dupixent in bullous pemphigoid; Q1 earnings April 29, 2026.Positive▶
Sanofi and Regeneron's Dupixent approved in Japan for bullous pemphigoid in adults as first targeted medicine. Stock at $763.04, down 0.16%. Bernstein cut price target to $921 from $925; RBC raised to $779 from $765. Q1 2026 earnings due April 29, 2026. 21 analysts recommend Buy rating.
Apr 9Bank of America upgrades Regeneron to Buy, raises price target amid improving fundamentals and 2026 pipeline catalysts.Positive▶
Regeneron Pharmaceuticals received a significant upgrade from Bank of America to Buy from Underperform with a price target increase to $860 from $627, citing improving fundamentals and multiple 2026 catalysts. The company gained exclusive access to 300 million patient records through a strategic collaboration with TriNetX, with a planned investment of up to $200 million. FDA approval extended dosing intervals for EYLEA HD up to 20 weeks for age-related macular degeneration and diabetic macular edema. Regeneron expects a $102 million R&D charge in Q1 2026 from acquisition-related activities. Q1 2026 earnings scheduled for April 29. The company is advancing a broad pipeline across oncology, obesity, and other therapeutic areas.
Apr 8Regeneron secures expanded EYLEA HD FDA approval enabling up to 5-month dosing intervalsPositive▶
Regeneron Pharmaceuticals received FDA approval extending EYLEA HD (aflibercept) dosing intervals up to every 20 weeks (5 months) for wet age-related macular degeneration and diabetic macular edema patients, based on 96-week data showing 47% of wAMD and 44% of DME patients achieved ≥20-week dosing intervals. The company reported strong Q4 2025 earnings with 3% revenue growth and $11.44 adjusted EPS. Regeneron announced collaboration with TriNetX to access de-identified EHR data from 300 million patients. Stock trading at $763.04 (-0.16% past 24h) with market cap of $76.89B. Analyst consensus Buy with average 12-month target of $873.24.
Apr 7Regeneron gets EYLEA HD extended dosing FDA approval; TriNetX partnership for 300M patient recordsPositive▶
Regeneron announced FDA approval for extended EYLEA HD dosing intervals up to 20 weeks for wAMD and DME (April 2). Dupixent approved Feb 24 for allergic fungal rhinosinusitis (AFRS) in ages 6+. Strategic TriNetX collaboration (April 2) provides access to 300M de-identified patient records for genomic/proteomic data. Phase 3 olatorepatide results positive: 19% mean weight loss, 97% achieved ≥5% weight loss in Chinese obesity cohort. Q1 2026 earnings April 29 at 8:30am. Stock down $16.42 (2.11%) on tariff concerns but analysts expect exclusion. Q4 2025: revenue +3%, adjusted EPS $11.44. Analyst consensus: Buy with $821.08 PT (+7.77%).
Apr 6Regeneron gains exclusive access to 300M patient records via TriNetX; launches immunology pipeline expansionPositive▶
Regeneron Pharmaceuticals announced strategic collaboration with TriNetX on April 2, 2026, gaining exclusive opportunity to connect large-scale genomic and proteomic data to TriNetX's network of ~300M de-identified patients. Regeneron will invest up to $200M in TriNetX as part of agreement. FDA approved extended dosing intervals for EYLEA HD (aflibercept) up to every 20 weeks for wet AMD and DME after one year of successful response—potentially requiring only 2-3 injections/year. Dupixent (dupilumab) approved in Japan for bullous pemphigoid. 2026 anticipated as pivotal with multiple regulatory filings and clinical milestones including late-stage oncology, obesity, complement-mediated diseases. Phase 3 allergen-specific programs presented for cat and birch allergies. Q1 2026 results due April 29 before market open with conference call at 8:30 a.m. ET. Q4 2025 EPS was $11.44, up from prior year. Analyst consensus is Buy with $821.08 PT (+7.8% upside). Strategic data access and strong pipeline drive positive outlook.
Apr 3Regeneron reports strong Q4 beat; EYLEA HD approved for extended dosing; Dupixent expands into new indications.Positive▶
Regeneron reported Q4 2025 adjusted EPS of $11.44 (beat consensus $10.71), with 3% revenue growth to $14.34B. FDA approved EYLEA HD as first/only injectable anti-VEGF with dosing intervals up to 5 months for wet AMD and DME. Dupixent approved in Japan for bullous pemphigoid. REGN7508 advanced to Phase 3 for cancer-linked blood clots.
Apr 2FDA approved EYLEA HD extended dosing intervals up to 20 weeks, a meaningful positive for Regeneron wet AMD and DME franchise as pipeline accelerates into 2026.Positive▶
The FDA approved extension of EYLEA HD dosing intervals up to every 20 weeks for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) patients after one year of successful response. Of patients completing week 96, 71% (wAMD) and 72% (DME) achieved 16-week or longer intervals; 47% (wAMD) and 44% (DME) reached 20-week intervals, potentially improving patient convenience and retention. Regeneron also received regulatory approval for Dupixent in Japan for bullous pemphigoid. Q1 2026 earnings will be reported April 29, 2026. Consensus analyst rating is Buy with 12-month target of $819.54 (+9.30% upside).
Apr 1Regeneron secured Japan approval for Dupixent in bullous pemphigoid and expects pivotal 2026 with multiple regulatory filings.Positive▶
Regeneron and Sanofi announced Japan's approval of Dupixent for treating moderate-to-severe bullous pemphigoid. Goldman Sachs initiated Buy rating and Wells Fargo raised price target to $825 from $800. The company anticipates a pivotal 2026 with multiple regulatory filings across six therapeutic areas.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABBVABBVIE | $207.05 | -2.02% | +2.2% | 13.1x | — | $373.8B |
| AMGNAMGEN | $330.27 | -4.62% | +1.1% | 14.8x | 0.47 | $186.7B |
| GILDGILEAD | $131.80 | +0.73% | -6.6% | 13.6x | 0.40 | $162.4B |
| VRTXVERTEX | $425.02 | -0.55% | -1.6% | 19.6x | 0.37 | $108.7B |
| REGNREGENERON | $702.19 | -0.69% | -7.3% | 13.0x | 0.40 | $74.1B |
| BIIBBIOGEN | $187.16 | -1.12% | +9.8% | 11.9x | 0.16 | $27.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price between 50d and 200d. Testing 50d support.